L1CAM Antibodies

Structure of L1CAM

L1CAM is a transmembrane glycoprotein with a molecular weight of approximately 200-220 kDa. Its actual molecular weight shows a wide range in electrophoresis due to the varying degrees of glycosylation modification. The following table shows the typical performance in different common experimental species or cell models:

This protein is composed of 1,257 to 1,287 amino acids, and its extracellular region contains multiple immunoglobulin (Ig) -like and fibronectin III (FnIII) repeat domains, which jointly mediate homologous and heterologous intercellular adhesion interactions. Its single transmembrane domain is connected to a highly conserved intracellular tail, which can bind to various intracellular signal-adapting proteins (such as ANKYRIN) to conduct extracellular adhesion signals into the cell, thereby regulating cell migration, axon growth and neuronal survival.

Fig. 1 L1CAM structure.¹

Key structural properties of L1CAM:

• Multidomain extracellular structures (including Ig-like and FNiII-like repetitive domains)
• Single transmembrane helical connection of intracellular and extracellular functional domains
• Conservative intracellular tail ANKYRIN combining motif
• Calcium dependent homologous/heterologous affinity interaction interface
• High glycosylation modification affects its mobility and recognition specificity

Functions of L1CAM

L1CAM is a transmembrane glycoprotein whose main function is to mediate intercellular adhesion and signal transduction, especially playing a core role in the development of the nervous system. However, it is also widely involved in a variety of pathophysiological processes, including cancer metastasis and neurodegenerative diseases. Its core functions can be summarized as follows:

The interaction network between L1CAM and other cell adhesion molecules is extremely complex, and its function is highly dependent on cell type, post-translational modifications (such as glycosylation), and microenvironmental signals. Unlike single-function oxygen storage proteins, L1CAM is more like a multifunctional "signal hub", and its scope and intensity of action depend on the molecular and cellular background in which it is located.

Applications of L1CAM and L1CAM Antibody in Literature

1. Angiolini, Francesca, and Ugo Cavallaro. "The pleiotropic role of L1CAM in tumor vasculature." International journal of molecular sciences 18.2 (2017): 254. https://doi.org/10.3390/ijms18020254

The article indicates that L1CAM is abnormally expressed in tumor blood vessels, has a pro-angiogenic effect, and hinders vascular normalization. Targeting L1CAM may become a novel therapeutic strategy for anti-angiogenesis and promoting vascular normalization, and is expected to improve the therapeutic effect of tumors.

2. Romani, Chiara, et al. "L1CAM expression as a predictor of platinum response in high‐risk endometrial carcinoma." International Journal of Cancer 151.4 (2022): 637-648. https://doi.org/10.1002/ijc.34035

Studies have shown that high expression of L1CAM is associated with poor response to platinum-based chemotherapy and a poor prognosis in patients with high-risk endometrial cancer, and it is expected to serve as a predictive biomarker for optimizing the efficacy of platinum-based chemotherapy.

3. Loers, Gabriele, Ute Bork, and Melitta Schachner. "Functional Relationships between L1CAM, LC3, ATG12, and Aβ." International journal of molecular sciences 25.19 (2024): 10829. https://doi.org/10.3390/ijms251910829

Research has revealed that the cell adhesion molecule L1 mediates autophagy by interacting with proteins such as LC3 and ATG12, promoting the clearance of β -amyloid protein, and is expected to provide a new therapeutic strategy for Alzheimer's disease by enhancing L1 function.

4. Dräger, Oliver, et al. "Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets." Molecular oncology 16.4 (2022): 957-981. https://doi.org/10.1002/1878-0261.13054 

Studies have revealed that L1CAM is highly expressed in retinoblastoma and can promote tumor growth, drug resistance and metastasis. Targeting L1CAM or its splicing enzyme can inhibit tumor progression, providing a new strategy for the treatment of this intraocular malignant tumor in children.

5. Giordano, Marco, et al. "L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling." Journal of Experimental & Clinical Cancer Research 40.1 (2021): 319. https://doi.org/10.1186/s13046-021-02117-z

Research has revealed that L1CAM is highly expressed in ovarian cancer stem cells and drives tumorigenesis and chemotherapy resistance by activating the FGFR1/SRC/STAT3 pathway. Its monoclonal antibody can inhibit the characteristics of stem cells, providing a new direction for targeted therapy.

Creative Biolabs: L1CAM Antibodies for Research

Creative Biolabs specializes in the production of high-quality L1CAM antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom L1CAM Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our L1CAM antibodies, custom preparations, or technical support, contact us at email.